I built the branding and visual identity for the SunRISe studies, a family of trials (SunRISe-1 through SunRISe-4) evaluating TAR-200, an investigational drug delivery system, in combination with cetrelimab, an anti-PD-1 therapy, across both muscle-invasive and non-muscle-invasive bladder cancer. I designed a flexible identity system that stayed consistent across each study while remaining clear and approachable for patients and clinical teams alike.